Directory of Pharma Companies and News
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofiâ€™s programs in oncology and immunology.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|2017-10-17||More than 30 Presentations of New Investigational Data from Sanofi Genzymeâ€™s Multiple Sclerosis Franchise to be Featured...|
|2017-10-16||Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eo...|
|2017-10-11||Internationally Acclaimed Writer and Executive Producer of HBOâ€™s The Night Of Reveals His Personal Story Detailing the H...|
|2017-09-28||Sanofi and Regeneron Announce Approval of DupixentÂ® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic D...|
|2017-09-20||Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amy...|
|2017-09-16||Sanofi and Regeneron Announce Positive Study Results for DupixentÂ® (dupilumab) in Patients With Moderate-to-Severe Atopi...|
|2017-09-11||Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma|
|2017-09-08||Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced ...|
|2017-09-07||Sanofi Alliance Partner Alnylam Provides Update on Fitusiran Development Program|
|2017-07-21||Sanofi and Regeneron Receive Positive CHMP Opinion for DupixentÂ® (dupilumab) to Treat Adult Patients with Moderate-to-Se...|